Emergent BioSolutions this week announced it entered into a definitive agreement to sell its Baltimore-Camden drug product facility. The Gaithersburg, Maryland-based company will sell the facility to an affiliate of Bora Pharmaceuticals for approximately $30 million. Emergent’s Camden site is part of the company’s Contract Development and Manufacturing Organization (CDMO) and has clinical and commercial…

Thermo Fisher Scientific has expanded its clinical research laboratory building at its good manufacturing practices (GMP) lab in Middleton, Wisconsin. The new $58 million investment adds 72,500 sq ft. to the company’s footprint and increases the site’s chemistry, manufacturing, and control analytical capabilities for biopharmaceutical therapy development. “As research in biopharmaceutical therapies continues to rapidly…

Vetter recently announced it is expanding its development services sites in the U.S. and is planning for major investments in Germany. The company announced plans to move and expand its Development Services site from Skokie, Illinois, to Des Plaines, Illinois. It plans to invest majorly in its commercial business in Saarland, Germany, to complement its…

Molecular Devices recently announced it opened its custom-built bioanalytical site in the U.K. The new facility is based in Cardiff, Wales, and is custom-built for the company’s bioprocess workflow and unique bioreactor technology. Molecular Devices’ biotechnology allows pharmaceutical companies to manufacture patient-derived organoids (PDOs) at scale in a quality-controlled manner. “Molecular Devices is the only…

Lotte Biologics and Merck recently signed a strategic partnership deal for biopharmaceutical manufacturing and process development. Through the agreement, Merck and Lotte Biologics will ensure the supply of essential raw materials and solutions for biopharmaceutical development and production, establish a stable supply chain system for raw materials, and develop a support system for the Bio…

Schreiner MediPharm this week launched its late-stage customization capabilities for its RFID-Labels series. The new offering allows the company’s smart labels to be supplied quickly with order-specific programming for integrated RFID chips. Schreiner MediPharm’s RFID functional labels give pharmaceutical companies the flexibility and agility to provide the best possible security of supply and quality assurance…

Ferring Pharmaceuticals and SK pharmteco today announced an agreement to scale up commercial manufacturing capacity for Ferring’s drug substance intravesical non-replicating gene therapy, Adstiladrin. The deal will help ensure the long-term future supply of gene therapy. Following the technology transfer, SK pharmteco will be qualified as another source for manufacturing, testing and release of the…

TriLink BioTechnologies today announced it opened its new cGMP mRNA manufacturing facility. The new 32,000 sq. ft. facility, based in San Diego, is specifically designed for mRNA manufacturing. Using the company’s mRNA manufacturing capabilities, it will support late-phase drug developers from Phase 2 to commercialization. TriLink said the opening is expected to help advance the…

KBI Biopharma this week announced it appointed Jean-Baptiste Agnus as chief business officer, effective immediately. Angus has more than two decades of experience across various sectors of the biopharmaceutical industry with expertise in commercial development in biologics, small molecule APIs, antibody-drug conjugates, and cell and gene therapies. As chief business officer, Angus will lead KBI’s…

Sen-Jam Pharmaceutical this week announced it is partnering with specialty pharmaceutical manufacturer KVK-Tech for formulation and chemistry, manufacturing and controls for anti-inflammatory injectables. The partnership is the third development, manufacturing, distribution and license agreement the pair have signed. The new partnership will further advance Sen-Jam’s first injectable anti-inflammatory therapeutic, SJP-100. Sen-Jam is developing an immunomodulator…